In a patient with metastatic HER2 positive breast cancer who has received prior TDM1 in the adjuvant setting for residual disease, would you consider reintroduction of TDM1?   

The patient is intolerant to trastuzumab deruxtecan. In which clinical settings would you consider reintroduction of TDM1?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at OhioHealth Physician Group
Thank you. Patient has progressed 6 months after c...
Medical Oncologist at Ohio State University
You can try that, although the likelihood of respo...
Medical Oncologist at OhioHealth Physician Group
Thank you.
Sign in or Register to read more